InvestorsHub Logo
Followers 28
Posts 4326
Boards Moderated 1
Alias Born 09/22/2006

Re: stockrafter post# 8383

Friday, 03/15/2024 10:35:08 AM

Friday, March 15, 2024 10:35:08 AM

Post# of 8531
FRom the article you posted recently

Based on these findings, the researchers concluded that CAB200 with rHuPH20 has “low potential” for less frequent dosing, and it will not move forward. But the new ultra-long-acting formulation has a favorable tolerability and safety profile with a pharmacokinetic profile that supports dose intervals of four months or more.


https://www.poz.com/article/ultralongacting-cabotegravir-given-every-four-months

The more you know, the less you don't know.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News